Cellectis’ TALE Epigenetic Editors Achieve >90% Gene Knock-down in T-cells and Hepatocytes
Cellectis achieved over 90% stable knock-down of two target genes in T-cells and hepatocytes using a TALE-based epigenetic editing platform, showcased in a poster at ASGCT’s May meeting. The high-throughput multiplex screening system rapidly assembled and tested hundreds of TALE-based epigenetic modulators without cutting DNA.
1. Platform Overview
Cellectis developed a TALE-based epigenetic editing platform that guides engineered fusion proteins to specific genome sites to silence or activate genes without introducing DNA breaks or permanent sequence changes.
2. High-Throughput Screening System
The company’s novel multiplex screening system can assemble and test hundreds of TALE-based epigenetic modulators rapidly, enabling identification of the most potent combinations for gene regulation.
3. Experimental Results
Using this platform, Cellectis demonstrated over 90% reduction in activity for a liver-expressed gene in hepatocytes and a T-cell dysfunction-related gene, with knock-down remaining stable throughout the study period.
4. Presentation Details
Cellectis will present these findings in a poster session at the ASGCT annual meeting on May 13, with the poster published on the company’s website at 5:00 pm ET on presentation day.